At a glance
ClinicalIndex Comparison RecordPhase 2Active· 18 enrolled / 18 target
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and IMGN853 for Endometrial Cancer. Active but no longer recruiting, targeting 18 participants across 3 sites.
Signals
Enrollment appears stalled
Detailed Summary
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
CollaboratorsImmunoGen, Inc., Merck Sharp & Dohme LLC
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedFeb 2019
Enrollment StartJan 2020
Primary CompletionJun 2024
TodayJul 2026
Study CompletionFeb 2027
First PostedFeb 11, 2019
Enrollment StartJan 2, 2020
Primary CompletionJun 4, 2024
Study CompletionFeb 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.4 years ago
Arms & Interventions
IMGN853 + Pembrolizumabexperimental
* Pembrolizumab is administered intravenously once every 3 weeks * IMGN853 is administered intravenously once every 3 weeks
Drug: PembrolizumabDrug: IMGN853
Interventions
Pembrolizumabdrug
Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
IMGN853drug
Mirvetuximab soravtansine is an antibody-drug conjugate.